Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can blood filtering or a cancer drug save kidneys in myeloma patients?

NCT ID NCT06483139

Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study looks at two treatments—plasma exchange (a blood-filtering procedure) and the drug daratumumab—to see if they help patients with multiple myeloma recover from acute kidney injury caused by light chain cast nephropathy. Researchers will track 450 adults to see who survives with better kidney function within 90 days. The goal is to find which approach works best for this serious complication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Daratumumab (a drug) and plasma exchange (a procedure that filters the blood)
What this could lead to
If successful, this could show that plasma exchange or daratumumab helps more patients recover kidney function after myeloma-related kidney injury.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove cause and effect. Kidney recovery depends on many factors, and benefits may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

549 people

The number who actually took part.

Started

Jun 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with multiple myeloma and clinically-suspected or biopsy-proven light chain cast nephropathy

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Plasma Exchange-Treated Patients: 1. Adult (≥18 years old) 2. Either a new diagnosis of multiple myeloma confirmed by bone marrow plasmayctosis \>10% or acute relapse of multiple myeloma 3. Light chain cast nephropathy, with involved light chain \>500 mg/L 4. Acute kidney injury, defined as ≥1.5-fold rise in SCr from baseline (as defined in study outcomes) or the need for renal replacement therapy (RRT). 5. Treated with at least 1 round of plasma exchange within 30 days of diagnosis of cast nephropathy 6. Treated with plasma exchange in 2010 or later Inclusion Criteria for Control Patients: 1. Adult (≥18 years old) 2. Either a new diagnosis of multiple myeloma confirmed by bone marrow plasmayctosis \>10% or acute relapse of multiple myeloma 3. Light chain cast nephropathy, with involved light chain \>500 mg/L 4. Acute kidney injury, defined as ≥1.5-fold rise in SCr from baseline or the need for renal replacement therapy (RRT) Exclusion Criteria for Both Plasma Exchange-Treated Patients and Control Patients: 1. Patients with end stage kidney disease 2. Patients with amyloidosis or monoclonal immunoglobulin deposition disease 3. Patients with chronic lymphocytic leukemia, plasma cell leukemia, or Waldenstrom's 4. Moribund condition (e.g., patients who died within 48 hours of initiation of plasma exchange) 5. Active urinary tract obstruction on renal imaging 6. Patients with significant albuminuria (≥2+ on urinary dipstick or \>10% fraction on UPEP) 7. Patients with other biopsy-proven causes of AKI (non-cast nephropathy lesions) 8. Patients who did not receive clone-directed therapy for myeloma 9. Patients who received plasma exchange \>30 days from the time of diagnosis of cast nephropathy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury light chain deposition disease plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Light chain nephropathy Multiple myeloma

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.